New Pharmaceuticals research report from Datamonitor is now available

Aug. 18, 2010 - PRLog -- In 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between 2005 and 2009. Datamonitor expects the market to grow to $1.2 billion by 2014. However, from 2015 to 2019, sales across the seven major markets will decline due to patent expiries of key drugs such as Baraclude and Viread, and reach approximately $893m by 2019.

Scope

* Analysis of the current hepatitis B market dynamics across the US, 5EU, Japan and Turkey, with a snapshot of the Rest of World countries
* Thorough assessment of key marketed products for hepatitis B therapy
* Detailed ten-year sales forecasts for marketed hepatitis B drugs in each of the seven major markets and Turkey
* Review of opinions of key hepatitis B opinion leaders on future market developments

Highlights

In 2009, small molecule antivirals dominated the hepatitis B market with sales of $954m. In comparison, sales of interferon products were low, accounting for only 3% of total hepatitis B sales in 2009. This low market share can be attributed to the high cost of interferon products, their restricted use and inconvenient mode of administration.

Market growth until 2014 will be driven by the strong uptake of newer hepatitis B antivirals such as Bristol-Myers Squibb's Baraclude (entecavir) and Gilead's Viread (tenofovir). Older products such as Gilead's Hepsera (adefovir) and GlaxoSmithKline's Zeffix (lamivudine) will be used less frequently owing to the increased risk of resistance.

In 2009, Baraclude was the best selling brand in terms of value in Turkey; however Zeffix dominated in terms of volume. The popularity of Zeffix can be explained by the stringent reimbursement policy in Turkey, which restricts the use of more expensive drugs such as the pegylated interferons, Baraclude and Viread to specific populations.

Reasons to Purchase

* Understand the changing market dynamics of hepatitis B drugs and success factors for leading brands.
* Assess the impact of events such as patent expiries on the overall hepatitis B market.
* Obtain full, country, class and product-specific forecasts of currently marketed drugs from 2009 to 2019 for all seven major markets and Turkey.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/76292_forecast_insight_hepatit...

Partial Table of Contents:

Overview 1
Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Infectious Diseases pharmaceutical analysis team 2
Executive Summary 2
Strategic scoping and focus 2
Datamonitor insight into the Hepatitis B market 2
Related reports 4
Upcoming related reports 4
Table of Contents 5
Table of figures 6
Table of tables 7
Market definition and overview 8
Market definition for this report 8
Countries and regions included in this report 8
Seven major market assessment 9
Current and future market overview 9
Small molecule antivirals will continue to dominate sales 10
Pegylated interferon sales to remain steady over the forecast period 12
Genericization will lead to an overall decline in sales across the seven major markets 14
Impact of vaccination will reduce hepatitis B incidence but immigration will keep prevalence rates stable across the seven major markets 15
US healthcare reform will increase the number of patients accessing therapy 17
EU countries are increasingly looking to cut healthcare spending 18
Japan implements biennial price cuts to contain costs 19
Comparison with previous forecast 19
Viread achieves higher peak sales, reflecting the drug's fast uptake 21
Combination therapy is unlikely to be used in first-line therapy in the near future 21
Tyzeka/Sebivo sales forecast was dampened due to poor uptake across the US and five major European markets 23
Clevudine has been excluded from the 2010 forecasts 23
Pegasys uptake has been slower than anticipated owing to the success of Baraclude and Viread 24
Rest of the world snapshot 24
Brand Dynamics 28
Overview of the competitive landscape 28
Small molecule antivirals 30
Viread HBV (tenofovir disoproxil fumarate; Gilead Sciences) 30
High efficacy and genetic barrier to resistance wins recommendation for first-line therapy 30
Viread is anticipated to be market leader by 2016, but generic incursion will slow growth thereafter 32
Baraclude (entecavir, Bristol-Myers Squibb) 33
Lack of differentiation between Baraclude and Viread will intensify competition in the first-line 34
Zeffix resistance restricts Baraclude's role in second-line therapy 35
Baraclude's patent expiry in 2015-16 will negatively impact Baraclude and Viread sales 36
Hepsera (adefovir dipivoxil; Gilead Sciences) 38
Hepsera use is set to decline following the introduction of Viread 39
Pegylated interferons 40
Pegasys (peginterferon alpha-2a, Roche) 40
Limited role in hepatitis B therapy will prevent further growth 41
Biosimilar uptake will remain low following Pegasys's patent expiry in 2017 42
Turkey 43
Market overview 43
General characteristics 43
Demographics 43
Economics 45
Healthcare spending and access 46
Reimbursement 47
Intellectual property environment 48
Drug approval process 48
Drug pricing 49
Treatment guidelines 50
Hepatitis B epidemiology 50
Current and future overview of the hepatitis B market in Turkey 51
Initial market growth will be followed by sales decline as genericization increases 51
Baraclude and Viread will emerge as clear market leaders as resistance against Zeffix increases 52
Bibliography 55
Journal papers 55
Websites 56
Datamonitor reports 58

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=7629...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.